CURE

What Subcutaneous Keytruda Means for Patients With Melanoma

The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...
Benzinga.com

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion

Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...
Nasdaq

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial ...
MedPage Today

Subcutaneous Alzheimer's Drug May Be on the Horizon

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Weekly ...

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

Viehbacher, “Biogen”) announced today that LEQEMBI ® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by ...
Healio

FDA approves Opdivo as subcutaneous injection

Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...
Nasdaq

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Monthly Prescribing Reference

Buprenorphine Extended-Release SC Injection Under Review Again for Opioid Use Disorder

Credit: Getty Images. The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021. The Food and Drug Administration (FDA) has accepted the resubmitted New Drug ...
MedPage Today

Subcutaneous Ocrelizumab Not Inferior to IV Infusion

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MILAN -- An ...

PharmaJet® to Highlight the Benefits of Intradermal Needle-free Delivery and Expansion into the Self-Injection Pen Market at Upcoming PODD Conference

PharmaJet will deliver 2 presentations at the PODD conference on Oct. 27 focusing on current and future applications of their ...
WOOD-TV

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

The BLA is based on LEQEMBI subcutaneous (SC) sub-studies of the Phase 3 Clarity AD open-label extension (OLE) trial in individuals with early AD, which evaluated a range of subcutaneous doses. Data ...